

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/742,348	12/19/2003	Karen Linder	3102/2000	6401	
35743	7590 09/09/2004		EXAMINER		
	EVIN NAFTALIS & FI JAL PROPERTY DEPAR	JONES, DAMERON LEVEST			
919 THIRD AVENUE			ART UNIT	PAPER NUMBER	
NEW YORK,	NEW YORK, NY 10022			1616	
			DATE MAIL ED: 00/00/200	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/742,348	LINDER ET AL.			
Office Action Summary	Examiner	Art Unit			
	D. L. Jones	1616			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet w	with the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a within the statutory minimum of thi will apply and will expire SIX (6) MOI	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication.			
Status					
1) Responsive to communication(s) filed on 19 De	ecember 2003				
2a) This action is FINAL . 2b) ⊠ This action is non-final.					
Since this application is in condition for allowan closed in accordance with the practice under Expression in the practice of the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for allowance with the practice under Expression in the condition for all the condition for all the condition in th	ce except for formal mat	ters, prosecution as to the merits is 0.11, 453 O.G. 213.			
Disposition of Claims					
4) Claim(s) 85 and 86 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 85 and 86 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	n from consideration.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accept	pted or b)⊡ objected to l	by the Examiner.			
Applicant may not request that any objection to the di	rawing(s) be held in abeyan	nce. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Exa	on is required if the drawing(miner. Note the attached	(s) is objected to. See 37 CFR 1.121(d). I Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign p a) All b) Some * c) None of: 1. Certified copies of the priority documents I 2. Certified copies of the priority documents I 3. Copies of the certified copies of the priority application from the International Bureau (* See the attached detailed Office action for a list of 	have been received. have been received in Ap y documents have been i PCT Rule 17.2(a)).	oplication No received in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12/19/03.	Paper No(s).	ummary (PTO-413) /Mail Date formal Patent Application (PTO-152)			

Application/Control Number: 10/742,348

Art Unit: 1616

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 12/19/03 wherein the specification was amended; claims 1-84 were canceled; and claims 85 and 86 were added.

Note: Claims 85 and 86 are pending.

APPLCIANT'S INVENTION

2. Applicant's invention is directed to a method of radiotherapy as set forth in independent claim 85.

DOUBLE PATENTING REJECTIONS

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double

Application/Control Number: 10/742,348

Art Unit: 1616

patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 85 and 86 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,699,458. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are directed to a method of radiotherapy wherein a metal-ligand complex is administered to a subject. The claims differ in that the instant invention includes a third compound (formula lc) that is not present in the patented invention. Hence, the skilled practitioner in the art would recognize that species encompassed by formulae la and lb are encompassed in the patented invention.

112 REJECTIONS

- 5. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 6. Claims 85 and 86 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10/742,348 Page 4

Art Unit: 1616

Claims 85 and 86: The claims as written are ambiguous because it is unclear what 'thiol-protecting group' Applicant is referring to in the claims (i.e., see independent claim 85, line 14). Applicant is respectfully requested to clarify the claim in order that one may readily known what is encompassed by the instant invention.

<u>Claim 86</u>: The claim as written is ambiguous because it is unclear whether Applicant intended to add more text since there is no period at the end of the claim.

SPECIFICATION

7. The disclosure is objected to because of the following informalities: on page 3, lines 4 and 6, there are markings on the page. Applicant is requested to submit a clean copy.

Appropriate correction is required.

COMMENTS/NOTES

- 8. Applicant is respectfully requested to update the continuing data (e.g., serial number 10/015,208 is now US Patent No. 6,699,458).
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. 3:15 p.m..

Art Unit: 1616

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

D. L. Jones
Primary Examiner

Art Unit 1616

September 3, 2004